WO2003000891A3 - Protein-protein interactions in the inner ear - Google Patents

Protein-protein interactions in the inner ear Download PDF

Info

Publication number
WO2003000891A3
WO2003000891A3 PCT/EP2002/008065 EP0208065W WO03000891A3 WO 2003000891 A3 WO2003000891 A3 WO 2003000891A3 EP 0208065 W EP0208065 W EP 0208065W WO 03000891 A3 WO03000891 A3 WO 03000891A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polypeptides
protein interactions
interactions
inner ear
Prior art date
Application number
PCT/EP2002/008065
Other languages
French (fr)
Other versions
WO2003000891A2 (en
Inventor
Laurent Daviet
Pierre Legrain
Christine Petit
Batiste Boeda
Aziz El-Amraoui
Original Assignee
Hybrigenics Sa
Pasteur Institut
Laurent Daviet
Pierre Legrain
Christine Petit
Batiste Boeda
Aziz El-Amraoui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics Sa, Pasteur Institut, Laurent Daviet, Pierre Legrain, Christine Petit, Batiste Boeda, Aziz El-Amraoui filed Critical Hybrigenics Sa
Priority to AU2002321243A priority Critical patent/AU2002321243A1/en
Publication of WO2003000891A2 publication Critical patent/WO2003000891A2/en
Publication of WO2003000891A3 publication Critical patent/WO2003000891A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to protein-protein interactions involved in deafness or in hearing disorders and/or diseases. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
PCT/EP2002/008065 2001-06-21 2002-06-21 Protein-protein interactions in the inner ear WO2003000891A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002321243A AU2002321243A1 (en) 2001-06-21 2002-06-21 Protein-protein interactions in the inner ear

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29984801P 2001-06-21 2001-06-21
US60/299,848 2001-06-21
EP02290277 2002-02-05
EP02290277.9 2002-02-05

Publications (2)

Publication Number Publication Date
WO2003000891A2 WO2003000891A2 (en) 2003-01-03
WO2003000891A3 true WO2003000891A3 (en) 2003-11-20

Family

ID=26077617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008065 WO2003000891A2 (en) 2001-06-21 2002-06-21 Protein-protein interactions in the inner ear

Country Status (2)

Country Link
AU (1) AU2002321243A1 (en)
WO (1) WO2003000891A2 (en)

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BOLZ ET AL.: "Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D", NATURE GENETICS, vol. 27, January 2001 (2001-01-01), pages 108 - 112, XP001148408 *
CHEN ET AL.: "Molecular cloning and domain structure of human myosin-VIIa, the gene product defective in Usher syndrom 1B", GENOMICS, vol. 36, 1996, pages 440 - 448, XP002231594 *
DATABASE EM_HUM [online] EMBL; 11 January 2001 (2001-01-11), BOLZ ET AL.: "Homo sapiens cadherin related 23 (CDH23) mRNA, complet cds", XP002231599, retrieved from EBI Database accession no. AF312024 *
DATABASE EM_HUM [online] EMBL; 9 October 1996 (1996-10-09), CHEN ET AL.: "Human myosin VIIa long transcrript mRNA, complete cds", XP002231597, retrieved from EBI accession no. HSU55208 Database accession no. U55208 *
DATABASE EM_MUS [online] EMBL; 14 September 2000 (2000-09-14), VERPY ET AL.: "Mus musculus harmonin isoform a+ (Ush1c) mRNA, complete cds, alternativey spliced", XP002231600, retrieved from EBI Database accession no. AF228924 *
DATABASE SWISSPROT [online] 1 March 2001 (2001-03-01), VERPY ET AL.: "Harmonin isoform a1", XP002231601, retrieved from EBI Database accession no. Q9ES65 *
DATABASE SWISS-PROT [online] 16 October 2001 (2001-10-16), CHEN ET AL.: "Myosin VIIa", XP002231598, retrieved from EBI accession no. MY7A_HUMAN Database accession no. Q13402 *
KUESSEL-ANDERMANN P ET AL: "Vezatin, a novel transmembrane protein, bridges myosin VIIA to the cadherin-catenins complex", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 22, 15 November 2000 (2000-11-15), pages 6020 - 6029, XP002226212, ISSN: 0261-4189 *
STEEL ET AL.: "A genetic approach to understanding auditory function", NATURE GENETICS, vol. 27, February 2001 (2001-02-01), pages 143 - 149, XP002231596 *
VERPY ET AL.: "A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrom type 1C", NATURE GENETICS, vol. 26, September 2000 (2000-09-01), pages 51 - 55, XP002231595 *

Also Published As

Publication number Publication date
AU2002321243A1 (en) 2003-01-08
WO2003000891A2 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
WO2002086122A3 (en) Protein-protein interactions in adipocytes
WO2003046176A3 (en) Protein-protein interactions in human immunodeficiency virus
WO2005095457A3 (en) Immunoglobulins
WO2002099055A3 (en) Cips as modifiers of the p53 pathway and method of use
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002032374A3 (en) Methods for treating il-18 mediated disorders
EP1218368A4 (en) COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS
WO1999002552A3 (en) Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
WO2003087831A3 (en) Proteins involved in breast cancer
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
EP1558749A4 (en) Atypical protein kinase c isoforms in disorders of the nervous system and cancer
WO2002053726A3 (en) Protein-protein interactions in adipocyte cells
WO2002032286A3 (en) Protein-protein interactions in neurodegenerative diseases
WO2002033112A3 (en) Protein-protein interactions in neurodegenerative diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2003035833A3 (en) Modifier of the p53 pathway and methods of use
WO2002090544A3 (en) Protein-protein interactions in adipocyte cells (3)
UA72875C2 (en) Novel proteins which bind human <sub>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-amyloid peptide, polynucleotides which encode theM
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
WO2003045990A3 (en) Protein-protein interactions involving transforming growth factor beta signalling
WO2003000891A3 (en) Protein-protein interactions in the inner ear

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2004104360

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP